Initiate clinical studies of individualized neoantigen therapy in additional tumor types with Merck
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Feb 2024
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Moderna and Merck plan to initiate clinical studies in additional tumor types in 2024.”
What we found
Evidence strength A What the grades mean
The 2025 10-K says Moderna and Merck rapidly expanded clinical studies to several tumor types, with the 2024 timing attached to the Phase 3 enrollment clause, so the excerpts suggest expansion in 2024.
-
A Moderna 8-K filed 2025-01-13
“Moderna and Merck rapidly expanded clinical studies to additional tumor types” ✓ confirmed on the page
-
A Moderna 10-K filed 2025-02-21
“We and Merck have rapidly expanded clinical studies to several tumor types and completed enrollment of the Phase 3 clinical trial for adjuvant melanoma in 2024.” ✓ confirmed on the page
Market reaction: the shares moved -19.8% against the S&P 500 over the three sessions around the disclosure (10 Jan 2025 to 15 Jan 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Clinical studies of individualized neoantigen therapy in additional tumor types
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-MRNA-006217 · Corrections policy